Filing Flows › Medpace Holdings (MEDP) › Q2 2026 › vs Q1 2026
Medpace Holdings (MEDP) Q2 2026 vs Q1 2026 (quarter over quarter)
Medpace Holdings's revenue rose $727K (+0.1%) from $707M in Q1 2026 to $707M in Q2 2026. The biggest changes: Other −$18.5M (-8%); Metabolic +$8.1M (+4%); Oncology +$5.0M (+5%). Operating margin 20.8% against 20.0% (+0.7 pts).
Medpace Holdings, Q2 2026: revenue $707M (+17% year over year), operating margin 20.8%, net earnings $121M, operating cash flow $162M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 20.8% | 20.0% | +0.7 pts |
| Net margin | 17.2% | 17.5% | -0.4 pts |
| Free cash flow margin | 19.5% | 20.5% | -1.0 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Other | $219M | $238M | −$18.5M | -8% |
| Metabolic | $209M | $201M | $8.1M | +4% |
| Oncology | $98.3M | $93.3M | $5.0M | +5% |
| Cardiology | $82.9M | $80.2M | $2.7M | +3% |
| Central Nervous System | $60.0M | $56.3M | $3.7M | +7% |
| AVAI | $37.8M | $38.0M | −$248K | -0.7% |
| Revenue | $707M | $707M | $727K | +0.1% |
| Other income, net | $4.8M | $6.1M | −$1.2M | -21% |
| Operating profit | $147M | $142M | $5.3M | +4% |
| Costs & expenses | $561M | $565M | −$4.6M | -0.8% |
| Pre-tax earnings | $152M | $148M | $4.1M | +3% |
| SG&A | $48.1M | $47.9M | $186K | +0.4% |
| Other operating costs | $512M | $517M | −$4.8M | -0.9% |
| Net earnings | $121M | $124M | −$2.5M | -2% |
| Income tax | $30.3M | $23.7M | $6.6M | +28% |
| Depreciation & amortization | $6.7M | $6.9M | −$196K | -3% |
| Share-based compensation | $4.3M | $4.9M | −$570K | -12% |
| Working capital & other | $29.6M | $16.1M | $13.5M | +84% |
| Operating cash flow | $162M | $152M | $10.2M | +7% |
| Free cash flow (OCF − capex) | $138M | $145M | −$6.9M | -5% |
| Capital expenditures | $23.9M | $6.8M | $17.1M | +251% |
Questions
How much did Medpace Holdings's revenue grow quarter over quarter in Q2 2026?
Medpace Holdings's revenue rose $727K (+0.1%) from $707M in Q1 2026 to $707M in Q2 2026.
What drove Medpace Holdings's revenue change in Q2 2026?
Other −$18.5M (-8%); Metabolic +$8.1M (+4%); Oncology +$5.0M (+5%).